Apr 2, 2019 Oncolytics Biotech (R) Presents Positive Clinical Biomarker Data at the American Association for Cancer Research Annual Meeting 2019
Mar 28, 2019 Oncolytics Biotech (R) Announces a Publication Highlighting Synergistic Effect of Pelareorep with a Proteasome Inhibitor in Preclinical Models of Multiple Myeloma
Mar 1, 2019 Oncolytics Biotech(R) to Host Conference Call to Discuss Year End Financial Results and Operational Highlights
Feb 11, 2019 Oncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast Cancer
Dec 12, 2018 Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma
Dec 3, 2018 Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Presentation at the 60th American Society of Hematology Annual Meeting & Exposition
Nov 29, 2018 Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical Officer
